Jean-Baptiste Brunet de Courssou

Jean-Baptiste Brunet de Courssou

Auto-generated profile, based on publicly available information

Jean-Baptiste Brunet de Courssou

Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France; AP-HP, Hôpital Bicêtre, DMU Neurosciences, Neurology Department, 94276 Le Kremlin-Bicêtre, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Brain
Verified
Journal Article
Closed access
JCJean-Baptiste Brunet de Courssou
Jean-Baptiste Brunet de Courssou
ADAlexandra Durr
Alexandra Durr
DADavid Adams
David Adams
JCJean-Christophe Corvol
Jean-Christophe Corvol
LMLouise-Laure Mariani
Louise-Laure Mariani
Advances in targeted regulation of gene expression allowed new therapeutic approaches for monogenic neurological diseases. Molecular diagnosis has paved the way to personalized medicine targeting the pathogenic roots: DNA or its RNA transcript. These antisense therapies rely on modified nucleotides sequences (single-strand DNA or RNA, both belonging to the antisense oligonucleotides family, or double-strand interfering RNA) to act specifically on pathogenic target nucleic acids, thanks to complementary base pairing. Depending on the type of molecule, chemical modifications and target, base pairing will lead alternatively to splicing modifications of primary transcript RNA or transient messenger RNA degradation or non-translation. The key to success for neurodegenerative diseases also depends on the ability to reach target cells. The most advanced antisense therapies under development in neurological disorders are presented here, at the clinical stage of development, either at phase 3 or market authorization stage, such as in spinal amyotrophy, Duchenne muscular dystrophy, transthyretin-related hereditary amyloidosis, porphyria and amyotrophic lateral sclerosis; or in earlier clinical phase 1 B, for Huntington's disease, synucleinopathies and tauopathies. We also discuss antisense therapies at the preclinical stage, such as in some tauopathies, spinocerebellar ataxias or other rare neurological disorders. Each subtype of antisense therapy, antisense oligonucleotides or interfering RNA, has proved target engagement or even clinical efficacy in patients; undisputable recent advances for severe and previously untreatable neurological disorders. Antisense therapies show great promise, but many unknowns remain. Expanding the initial successes achieved in orphan or rare diseases to other disorders will be the next challenge, as shown by the recent failure in Huntington disease or due to long-term preclinical toxicity in multiple system atrophy and cystic fibrosis. This will be critical in the perspective of new planned applications to premanifest mutation carriers, or other non-genetic degenerative disorders such as multiple system atrophy or Parkinson disease.

3 February 2022 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
JCJean-Baptiste Brunet de Courssou
Jean-Baptiste Brunet de Courssou
MTMylène Tisseyre
Mylène Tisseyre
JHJérôme Hadjadj
Jérôme Hadjadj
LCLaurent Chouchana
Laurent Chouchana
FBFlorent Broca
Florent Broca
SHSoledad Henriquez
Soledad Henriquez
To describe a case of Vogt-Koyanagi-Harada (VKH) disease after a Covid-19 mRNA vaccine (tozinameran) and to present the results of a pharmacovigilance disproportionality study.A retrospective chart...

1 April 2022 in Revue Neurologique
Verified
Journal Article
Closed access
JCJ.-B. Brunet de Courssou
J.-B. Brunet de Courssou
MCM.A. Castilla-Lievre
M.A. Castilla-Lievre
JMJean Maillot
Jean Maillot
MBM.-L. Brechemier
M.-L. Brechemier
COC. Ohlmann
C. Ohlmann
ITI. Taifas
I. Taifas

14 August 2025 in Revue Neurologique
Verified
Journal Article
Open access
JCJ.-B. Brunet de Courssou
J.-B. Brunet de Courssou
LGL. Gorza
L. Gorza
MBM. Babin
M. Babin
GNG. Nasser
G. Nasser
CAC. Ancelet
C. Ancelet
CCC. Cauquil
C. Cauquil
Hereditary transthyretin amyloidosis (ATTRv) is the most common hereditary amyloidosis, affecting mainly the peripheral nervous system and the heart. Central nervous system (CNS) involvement is regarded as rare, apart in some TTR variants, although leptomeningeal amyloid deposit had been described in the frequent Val30Met variant. Cerebral amyloid angiopathy (CAA) is a neurovascular disease characterized by amyloid deposits in brain vasculature, leading to ischemic and hemorrhagic events. The main cause is sporadic CAA with β-amyloid deposits but hereditary causes are possible. We analyzed a cohort of ATTRv symptomatic patients treated at Bicêtre university hospital who underwent brain magnetic resonance imaging (MRI) regardless of indication. Twenty out of 64 ATTRv patients (31%) fulfilled radiological criteria of possible or probable CAA (suspected CAA) according to the modified Boston criteria with an unusually high 77% (10/13) frequency of leptomeningeal enhancement. Clinically, suspected CAA patients tended to have more focal central neurological symptoms, seizures and memory complaints than ATTRv patients without those MRI features. ATTRv-related CAA should be considered in case of CAA with suggestive systemic features or familial history, as specific treatments and genetic counseling now exist for ATTRv. Conversely, CNS symptoms and brain MRI abnormalities should be sought in ATTRv patients.

1 February 2020 in Pratique Neurologique - FMC
Verified
Journal Article
Closed access
JCJ.-B. Brunet de Courssou
J.-B. Brunet de Courssou
WEW. Ekue
W. Ekue
CNC. Nardin
C. Nardin

18 August 2022 in Pratique Neurologique - FMC
Verified
Journal Article
Closed access
JCJ.-B. Brunet de Courssou
J.-B. Brunet de Courssou
COC. Ohlmann
C. Ohlmann
SMS. Madec
S. Madec
MLM.-N. De La Lance
M.-N. De La Lance
CDC. Doutrelon
C. Doutrelon
ITI. Taifas
I. Taifas